Pharvaris (NASDAQ:PHVS) Stock Price Down 7.4% – What’s Next?

Pharvaris (NASDAQ:PHVS) shares were down 7.4% during trading on Wednesday . The company traded as low as $19.00 and last traded at $19.00. Approximately 26,143 shares traded hands during trading, a decline of 70% from the average daily volume of 86,941 shares. The stock had previously closed at $20.51.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer increased their target price on shares of Pharvaris from $38.00 to $42.00 and gave the stock an “outperform” rating in a research report on Friday, September 6th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, Pharvaris currently has a consensus rating of “Moderate Buy” and a consensus price target of $33.60.

Pharvaris Stock Up 0.8 %

The company has a 50 day moving average of $20.77 and a 200 day moving average of $19.29.

Institutional Trading of Pharvaris

Several large investors have recently added to or reduced their stakes in PHVS. Public Employees Retirement System of Ohio bought a new position in shares of Pharvaris during the 3rd quarter valued at $57,000. Barclays PLC acquired a new position in Pharvaris during the third quarter worth $106,000. Geode Capital Management LLC raised its holdings in Pharvaris by 18.4% during the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock valued at $685,000 after buying an additional 5,753 shares in the last quarter. HighVista Strategies LLC lifted its position in shares of Pharvaris by 35.9% in the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock worth $422,000 after buying an additional 6,018 shares during the last quarter. Finally, Sofinnova Investments Inc. boosted its stake in shares of Pharvaris by 2.9% during the 2nd quarter. Sofinnova Investments Inc. now owns 601,534 shares of the company’s stock worth $11,309,000 after acquiring an additional 16,862 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.